EP4065239A1 - Combinaisons de principes actifs d'ubiquinol et d'ubiquinone, préparations cosmétiques ou dermatologiques contenant de telles combinaisons de principes actifs, et utilisation d'ubiquinol pour améliorer l'efficacité de préparations cosmétiques ou dermatologiques à teneur en ubiquinone - Google Patents

Combinaisons de principes actifs d'ubiquinol et d'ubiquinone, préparations cosmétiques ou dermatologiques contenant de telles combinaisons de principes actifs, et utilisation d'ubiquinol pour améliorer l'efficacité de préparations cosmétiques ou dermatologiques à teneur en ubiquinone

Info

Publication number
EP4065239A1
EP4065239A1 EP20800585.0A EP20800585A EP4065239A1 EP 4065239 A1 EP4065239 A1 EP 4065239A1 EP 20800585 A EP20800585 A EP 20800585A EP 4065239 A1 EP4065239 A1 EP 4065239A1
Authority
EP
European Patent Office
Prior art keywords
preparations
weight
skin
cosmetic
ubidecarenone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20800585.0A
Other languages
German (de)
English (en)
Inventor
Julia Maxi Weise
Alexandra Vogelsang
Nadine MOELLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP4065239A1 publication Critical patent/EP4065239A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to preparations containing ubiquinol and ubiquinone and their cosmetic or dermatological use for the care of aging skin, for the prophylaxis and treatment of senile xerosis, and for improved skin contouring or against cellulite.
  • Cosmetics can be used to summarize all measures that make changes to skin and hair for aesthetic reasons or that are used to cleanse the body. Cosmetics therefore means caring for, improving and beautifying the exterior of the body in order to please others as well as yourself in a visible, tangible and smellable way.
  • Another aim of skin care is to compensate for the loss of oil and water in the skin caused by daily washing. This is especially important when the natural regeneration capacity is insufficient.
  • skin care products should protect against environmental influences, in particular against sun and wind, and delay skin aging.
  • Chronological aging of the skin is caused, for example, by endogenous, genetically determined factors.
  • the following structural damage and functional disorders occur as a result of age, which can also fall under the term "Senile Xerosis”: a) Dryness, roughness and the formation of wrinkles caused by dryness, b) itching and c) reduced lipid replenishment by sebum glands (eg after washing).
  • Exogenous factors such as UV light and chemical noxae, can have a cumulative effect and, for example, accelerate or supplement the endogenous aging processes.
  • exogenous factors in particular lead to, for example, the following structural damage and functional disorders in the low tide, which go beyond the extent and quality of the damage caused by chronic aging: d) Visible vasodilatation (telangiectasia, cuperosis); e) sagging and wrinkling; f) local Flyper, Flypo and incorrect pigmentation (e.g. age spots) and g) increased susceptibility to mechanical stress (e.g. cracking) h) declining vitality and regeneration of the dullness.
  • the present invention relates in particular to products for the care of the naturally aged flaut, as well as the phenomena listed under a), e), f), g) and h).
  • Products for the care of slackened, in particular aged, dullness are known per se. They contain, for example, retinoids (vitamin A acid and / or its derivatives) or vitamin A and / or its derivatives.
  • retinoids vitamin A acid and / or its derivatives
  • vitamin A and / or its derivatives are known per se. They contain, for example, retinoids (vitamin A acid and / or its derivatives) or vitamin A and / or its derivatives.
  • vitamin A acid and / or its derivatives vitamin A and / or its derivatives.
  • Retinoids can therefore only be used in low concentrations.
  • the slack skin is often associated with obesity and / or the so-called cellullite that is often associated with it.
  • Cellulite - a widespread phenomenon - plays a central role in this.
  • the visible picture of cellulite is based on an increase in fat pads in the subcutis (subcutaneous fat tissue), a weak connective tissue and a reduction in the flow conditions in the blood and blood vessels Lymphatics.
  • the cause is thus a partially genetic weakening of the connective tissue with the simultaneous occurrence of enlarged fat cell chambers as a result of overweight, unbalanced diet, lack of exercise.
  • the development of cellulite can also be traced back to an increased permeability of the hair vessel walls, which allows water to penetrate into the connective tissue.
  • the object of the present invention was therefore to find ways which avoid the disadvantages of the prior art.
  • Coenzyme Q-10 is characterized by the following structural formula:
  • ubidecarenone in agents for tightening the skin is known per se, for example from EP 1 084701 A1.
  • One object of the present invention was to eliminate the disadvantages of the prior art. First and foremost, active ingredient combinations and / or preparations based on coenzyme Q10 should be made available, with the help of which the full - possibly even improved effectiveness of coenzyme Q10 can be achieved.
  • active ingredients or preparations containing such active ingredients should be made available which, when used, stimulate collagen synthesis, strengthen the dermo-epidermal junction (skin tightening) and visibly improve the condition of the skin.
  • active ingredients or preparations containing such active ingredients should be made available which can be used successfully for the care, prophylaxis and treatment of aging skin and / or senile xerosis.
  • the aim was to solve galenic problems such as brownish discolouration of the formulation, degradation of the light-sensitive antioxidants contained and skin intolerances, for example through oxidative degradation products. It was, however, surprising and unforeseeable for the person skilled in the art that active ingredient combinations of a) ubidecarenone (coenzyme Q10) b) ubidecarenol and preparations, in particular cosmetic or dermatological preparations containing a) ubidecarenone (coenzyme Q10) b) ubidecarenol and the use of such active ingredient combinations or preparations to improve the elasticity of the skin, hair and / or nails and therefore cellulite or that
  • preparations according to the invention to improve the skin surface structure, in particular to smooth the skin and to reduce skin dents in particular the use of preparations according to the invention to reduce cellulite is also considered to be an implementation of the present invention.
  • Ubiquinols are characterized by the following chemical structure:
  • n 10 predominates (ubidecarenol), which according to the invention is the preferred ubiquinol.
  • ubiquinols The cosmetic use of ubiquinols is known per se, for example from WO 2017/045034, DE 42 28 871 and other publications.
  • ubidecarenol to ubidecarenone from the range from 100: 1 to 1: 100, preferably 50: 1 to 1:50, particularly preferably 20: 1 to 1:20.
  • concentrations of 0.000.001 ( 10 6) to 5% by weight of coenzyme Q10 (ubidecarenone), preferably from 0.000.1 to 1% by weight, particularly preferably 0.001 to 0.5% by weight, in the finished preparations. -% to be selected, based on the total weight of the preparations.
  • concentrations of 0.000.001 ( 10 6) to 5% by weight of coenzyme Q10 (ubidecarenone), preferably from 0.000.1 to 1% by weight, particularly preferably 0.001 to 0.5% by weight, in the finished preparations. % to be selected, based on the total weight of the preparations.
  • active ingredient combinations according to the invention as an antioxidant and its use for combating and / or prophylaxis of skin aging and inflammatory reactions caused by oxidative stress.
  • a particularly advantageous embodiment of the present invention is also considered to be the use of active ingredient combinations according to the invention for combating and / or prophylaxis of oxidative stress.
  • the cosmetic or dermatological preparations according to the invention can have the usual composition and serve for the treatment, care and cleaning of the skin and / or hair and as a make-up product in decorative cosmetics. They contain preferably 0.001% by weight to 10% by weight, preferably 0.05% by weight to 5% by weight, in particular 0.01-2.0% by weight, based on the total weight of the Preparations of active ingredient combinations used according to the invention.
  • Complexing agents are known auxiliaries in cosmetology or medical galenics. By complexing interfering metals such as Mn, Fe, Cu and others, For example, undesired chemical reactions in cosmetic or dermatological preparations can be prevented.
  • Complexing agents in particular chelators, form complexes with metal atoms which, in the presence of one or more polybasic complexing agents, that is to say chelators, represent metallacycles.
  • Chelates are compounds in which a single ligand occupies more than one coordination point on a central atom. In this case, stretched compounds are normally closed to form rings by complex formation via a metal atom or ion. The number of bound ligands depends on the coordination number of the central metal. The prerequisite for chelation is that the compound reacting with the metal contains two or more atom groups that act as electron donors.
  • Cosmetic and dermatological preparations according to the invention can be in various forms.
  • they can be a solution, an anhydrous preparation, an emulsion or microemulsion of the water-in-oil (W / O) type or of the oil-in-water (O / W) type, a multiple emulsion, for example of the water-type in-oil-in-water (W / O / W), a gel, a solid stick, an ointment or an aerosol.
  • isoquercitrin in encapsulated form e.g. in collagen matrices and other common encapsulation materials, e.g. as cellulose encapsulation, in gelatine, wax matrices or liposomally encapsulated.
  • wax matrices as described in DE-OS 43 08 282 have proven to be favorable.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries such as are usually used in such preparations, for example preservatives, bactericides, perfumes, substances to prevent foaming, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers , softening, moisturizing and / or moisture-retaining substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • preparations according to the invention can also contain further antioxidants and / or radical scavengers.
  • the antioxidants are advantageously selected from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g.
  • carotenoids eg ⁇ -carotene, ⁇ -carotene, lycopene
  • ⁇ -hydroxy acids eg citric acid, lactic acid
  • EDTA iminodisuccinate
  • unsaturated fatty acids and their derivatives eg g-linolenic acid, linoleic acid, oleic acid
  • folic acid and their derivatives vitamin C and derivatives (e.g. ascorbyl palmate, sodium ascorbyl phosphate), tocopherols and derivatives (e.g.
  • vitamin E acetate
  • vitamin A and derivatives retinol, vitamin A palmitate
  • rutic acid and its derivatives vegetable polyphenols with a logP of 1 to 3, quercetin, isoflavones, genistein, genistin, daidzein, ⁇ -glucosyl rutin, ferulic acid, butylated hydroxytoluene, mannose, magnolia bark extract, magnolol, honokiol, milk thistle extracts; Silymarin, Licochalcone A, Creatine, Creatinine.
  • the amount of the aforementioned antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.01-20% by weight, in particular 0.1-10% by weight, based on the total weight of the preparation.
  • vitamin E and / or its derivatives represent the additional antioxidant (s)
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the additional antioxidant (s)
  • Emulsions according to the invention are advantageous and contain, for example, the fats, oils, waxes and other fatty substances mentioned, as well as water and an emulsifier as is customarily used for such a type of formulation.
  • the lipid phase can advantageously be selected from the following group of substances: Mineral oils, mineral waxes
  • Oils such as triglycerides of capric or caprylic acid, ester oils such as dicaprylyl ether, and also natural oils such as castor oil;
  • Fats, waxes and other natural and synthetic fatty substances preferably esters of fatty acids with alcohols of low carbon number, e.g. with isopropanol, propylene glycol or glycerine, or esters of fatty alcohols with alkanoic acids of low carbon number or with fatty acids or natural waxes, such as shea butter;
  • Silicone oils such as dimethicones, dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
  • the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions for the purposes of the present invention is advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms Atoms.
  • ester oils can then advantageously be chosen from the group isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-hexyl hexyl palmitate, 2-hexyl hexyl palmitate, 2- hexyl hexyl palmitate, 2- hexyl hexyl stearate, 2-hexyl stearate, 2-hexyl stearate.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, silicone oils, dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and fatty acid triglycerides, namely the triglycerol esters of saturated and / or unsaturated, ver branched and / or unbranched alkanecarboxylic acids with a chain length of 8 to 24, in particular special 12-18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be chosen from the group of synthetic, semi-synthetic and natural oils, for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like. Any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • synthetic, semi-synthetic and natural oils for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like. Any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, Ci2-15 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
  • hydrocarbons paraffin oil, squalane and squalene are to be used advantageously for the purposes of the present invention.
  • the oil phase can also advantageously have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Dimethicone is advantageously used as the silicone oil to be used according to the invention.
  • silicone oils can also be used advantageously for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • 4-tert-butyl-4'-methoxydibenzoylmethane is advantageous in cosmetic or dermatological preparations, preferably at 0.001% by weight to 10% by weight, preferably at 0.05% by weight to 5% by weight, in particular preferably 0.1-2.0% by weight, based on the total weight of the preparations.
  • the aqueous phase of the preparations according to the invention optionally contains advantageously alcohols, diols or polyols with a low carbon number, as well as their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or - monobutyl ether, diethy Lenglycol monomethyl or monoethyl ethers and analogous products, also alcohols with a low carbon number, e.g.
  • ethanol isopropanol, 1,2-propanediol, glycerol and, in particular, one or more thickeners, which can advantageously be selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides or their derivatives, for example hyaluronic acid, xanthan gum, hydroxypropylmethylcellulose, particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group of so-called carbon poles, for example carbopoles of types 980, 981, 1382, 2984, 5984, each individually or in Combination.
  • thickeners which can advantageously be selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides or their derivatives, for example hyaluronic acid, xanthan gum, hydroxypropylmethylcellulose, particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group of so-called carbon poles, for example carbopoles of types 980, 981, 1382
  • mixtures of the abovementioned solvents are used.
  • water can be another component.
  • Emulsions according to the invention are advantageous and contain, for example, the fats, oils, waxes and other fatty substances mentioned, as well as water and an emulsifier as is customarily used for such a type of formulation.
  • Gels according to the invention usually contain alcohols with a low carbon number, for example ethanol, isopropanol, 1,2-propanediol, glycerol and water or an above-mentioned oil in the presence of a thickener, which is preferably silicon dioxide or an aluminum silicate in oily-alcoholic gels , in the case of aqueous-alcoholic or alcoholic gels is preferably a polyacrylate.
  • a thickener which is preferably silicon dioxide or an aluminum silicate in oily-alcoholic gels , in the case of aqueous-alcoholic or alcoholic gels is preferably a polyacrylate.
  • Suitable propellants for preparations according to the invention which can be sprayed from aerosol containers are the customary, highly volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. It is also advantageous to use compressed air.
  • hydrocarbons propane, butane, isobutane
  • Preparations according to the invention can also advantageously contain further substances which absorb UV radiation in the UVA and / or UVB range, the total amount of the filter substances, for example 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1.0 to 6.0% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair or the skin from the entire range of ultraviolet radiation protect. They can also be used as sunscreen for hair or skin. If the preparations according to the invention contain UVB filter substances, these can be oil-soluble or water-soluble. Oil-soluble UVB filters which are advantageous according to the invention are, for example:
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomenthyl ester,
  • benzophenone preferably 2-flydroxy-4-methoxybenzophenone, 2-flydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
  • Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester, - 2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5-triazine.
  • Advantageous water-soluble UVB filters are, for example:
  • Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, as well as the sulfonic acid itself;
  • Sulfonic acid derivatives of benzophenones preferably 2-flydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
  • Sulfonic acid derivatives of 3-benzylidene camphor such as 4- (2-oxo-3-bornylidenemethyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidenemethyl) sulfonic acid and its salts and the 1,4 di (2-oxo-10-sulfo-3-bornylidenemethyl) benzene and its salts (the corresponding 10-sulfato compounds, for example the corresponding sodium, potassium or triethanolammonium salt), also as benzene-1,4 -di (2-oxo-3-bornylidenemethyl-10-sulfonic acid called
  • UVB filters which can be used in combination with the active substance combinations according to the invention, is of course not intended to be limiting.
  • the invention also relates to the use of a combination of the active ingredient combinations used according to the invention with at least one UVB filter as an antioxidant or the use of a combination of the active ingredient combinations used according to the invention combinations with at least one UVB filter as an antioxidant in a cosmetic or matological preparation.
  • Cosmetic and dermatological preparations with an effective content of active ingredient combinations used according to the invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, zirconium, silicon, manganese, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. Pigments based on titanium dioxide are particularly preferred.
  • the cosmetic and dermatological contain active ingredients and auxiliaries such as are customarily used for this type of preparations for hair care and hair treatment.
  • the auxiliaries used are preservatives, surface-active substances, substances to prevent foaming, thickeners, emulsifiers, fats, oils, waxes, organic solvents, bactericides, perfumes, dyes or pigments, the task of which is to treat the hair or the cosmetic or dermatological preparation itself to dye, electrolytes, substances against greasy hair.
  • the total Q10 content in the ubidecarenol-treated cells increases 2.6 times better than in the ubidecarenone-treated cells, which speaks for an improved bioavailability of the ubidecarenol for keratinocytes.
  • Example 1 O / W emulsion with light protection% by weight pH 6.8-7.8

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des combinaisons de principes actifs qui sont constituées a) d'ubidécarénone (coenzyme Q10) et d'ubidécarénol.
EP20800585.0A 2019-11-26 2020-10-27 Combinaisons de principes actifs d'ubiquinol et d'ubiquinone, préparations cosmétiques ou dermatologiques contenant de telles combinaisons de principes actifs, et utilisation d'ubiquinol pour améliorer l'efficacité de préparations cosmétiques ou dermatologiques à teneur en ubiquinone Pending EP4065239A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102019218245.3A DE102019218245A1 (de) 2019-11-26 2019-11-26 Wirkstoffkombinationen aus Ubichinol und Ubichinon, kosmetische oder dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend, und Verwendung von Ubichinol zur Verbesserung der Wirksamkeit kosmetischer oder dermatologischer Zubereitungen mit einem Gehalt an Ubichinon
PCT/EP2020/080138 WO2021104781A1 (fr) 2019-11-26 2020-10-27 Combinaisons de principes actifs d'ubiquinol et d'ubiquinone, préparations cosmétiques ou dermatologiques contenant de telles combinaisons de principes actifs, et utilisation d'ubiquinol pour améliorer l'efficacité de préparations cosmétiques ou dermatologiques à teneur en ubiquinone

Publications (1)

Publication Number Publication Date
EP4065239A1 true EP4065239A1 (fr) 2022-10-05

Family

ID=73043229

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20800585.0A Pending EP4065239A1 (fr) 2019-11-26 2020-10-27 Combinaisons de principes actifs d'ubiquinol et d'ubiquinone, préparations cosmétiques ou dermatologiques contenant de telles combinaisons de principes actifs, et utilisation d'ubiquinol pour améliorer l'efficacité de préparations cosmétiques ou dermatologiques à teneur en ubiquinone

Country Status (3)

Country Link
EP (1) EP4065239A1 (fr)
DE (1) DE102019218245A1 (fr)
WO (1) WO2021104781A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4308282C2 (de) 1993-03-16 1994-12-22 Beiersdorf Ag Vorzugsweise in Form von Mikrosphärulen vorliegende galenische Matrices
DE19944137A1 (de) 1999-09-15 2001-03-22 Beiersdorf Ag O/W-Emulsionen mit einem Gehalt an einem oder mehreren Biochinonen und einem erhöhten Gehalt an Glycerin
EP1871389A2 (fr) * 2005-04-01 2008-01-02 Zymes, LLC Enrichissement de la peau au moyen de coq 10 en tant que systeme d'administration
AU2008229662A1 (en) * 2007-09-26 2009-04-09 Blackmores Limited Nutrition supplement
WO2017045034A1 (fr) 2015-09-17 2017-03-23 Pharmako Biotechnologies Pty Limited Compositions d'ubiquinone et d'ubiquinol, et procédés associés

Also Published As

Publication number Publication date
DE102019218245A1 (de) 2021-05-27
WO2021104781A1 (fr) 2021-06-03

Similar Documents

Publication Publication Date Title
EP1406599B1 (fr) Preparations cosmetiques et dermatologiques a la creatine utilisees dans le traitement et la prevention active de la peau seche et d'autres modifications negatives de l'homeostase physiologique des peaux saines
WO2001003657A1 (fr) Agent pour usage topique a action protectrice et regeneratrice, comprenant de l'idebenone
WO2002009652A2 (fr) Utilisation d'associations contenant des carnitines
EP1049454B1 (fr) Preparations cosmetiques et dermatologiques contenant des concentrations d'electrolyte accrues
EP3524236A1 (fr) Utilisation du licochalchone a ou d'un extrait du radix glycyrrhizae inflatae contenant du licochalchone a contre le vieillissement cutané
DE10128910A1 (de) Verwendung von Wirkstoffkombinationen aus Arginin und Ascorbinsäure zur Hautstraffung
WO2014183973A1 (fr) Préparations stabilisées à teneur en acide ascorbique et en ions phosphate
EP3006015A1 (fr) Utilisation de combinaisons d'agents actifs provenant d'un ou plusieurs bioquinones et d'un ou plusieurs isoflavones destinées à améliorer le modelage
EP1733741A2 (fr) Emulsion H/E contenant un ou plusieurs bioquinones et un teneur de glycerine élevée
EP1214927A1 (fr) Utilisation de l' acide folique et/ou de ses dérivés pour la préparation de compositions topiques
EP3658112B1 (fr) Associations de principes actifs comprenant du n-(4-amino-2-méthylchinolin-6-yl)-2-((4-éthylphénoxy)méthyle)benzamide et un ou plusieurs agents et/ou adjuvants de conservation cosmétiquement ou dermatologiquement acceptables
EP0884048B1 (fr) Emulsions cosmétiques et dermatologiques contenant des alkylglucosides et des concentrations élevées d'électrolytes
EP2560666B1 (fr) Combinaisons des agents avec un extrait d' ecorce de magnolia et des agents actifs tensioactifs (polyglaceryl(3)-methylglucosedistearate)
EP2421502B1 (fr) COMPOSITION COMPRENANT l'ACIDE GLYCYRRHÉTINIQUE POUR RÉPARER DES DOMMAGES DÉJÀ SUBIS PAR L'ADN DE LA PEAU
WO2014183974A1 (fr) Préparations stabilisées à teneur en acide ascorbique, et mélanges de sodium stéaroyl glutamate et/ou de cétyl stéaryl sulfate en association avec du glycéryl stéarate
DE29924371U1 (de) O/W-Emulsionen mit einem Gehalt an einem oder mehreren Biochinonen und einem erhöhten Gehalt an Glycerin
WO2016078853A1 (fr) Préparations contenant de l'acide ascorbique, de l'ubidécarénone et un mélange émulsifiant
EP3644953A1 (fr) Utilisation de n-(4-amino-2-méthylchinolin-6-yl)-2-((4-éthylphénoxy)méthyl)benzamide pour produire des préparations cosmétiques ou dermatologiques destinées au traitement thérapeutique et/ou prophylactique des symptômes du vieillissement cutané intrinsèque et/ou extrinsèque, ainsi que pour le traitement thérapeutique et prophylactique des effets nocifs des rayons ultraviolets sur la peau
EP4065239A1 (fr) Combinaisons de principes actifs d'ubiquinol et d'ubiquinone, préparations cosmétiques ou dermatologiques contenant de telles combinaisons de principes actifs, et utilisation d'ubiquinol pour améliorer l'efficacité de préparations cosmétiques ou dermatologiques à teneur en ubiquinone
EP1834631B1 (fr) Préparations cosmétiques ou dermatologiques contenant de la glycyrrhétine et/ou de la glycyrrhizine et des dérivés de glucose ou des ethers de glycérine
DE10316666B4 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin mit Kreatin und Coenzym Q10
DE10121069A1 (de) Verwendung von Tetrahydrocurcuminoiden oder deren Derivaten als Wirkstoffe zur Herstellung von kosmetischen und dermatologischen Zubereitungen zum Schutz und zur Behandlung der trockenen bzw. alterstrockenen Haut
WO2016078854A1 (fr) Préparations contenant de l'acide ascorbique, de l'ubidécarénone et des ions phosphate pour un remodelage amélioré de la peau ou contre la cellulite
DE102015207267A1 (de) Verwendung von Hibifolin gegen Hautalterung
WO2009030302A1 (fr) Combinaison de substances actives constituée d'acide glycyrrhétinique et de dihydroxyacétone et préparations cosmétiques ou dermatologiques qui contiennent ces combinaisons de substances actives

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220627

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231214

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BEIERSDORF AG